Login to Your Account

Earnings Roundup

Monday, January 30, 2012
• Amgen Inc., of Thousand Oaks, Calif., reported full-year 2011 earnings reflecting a revenue increase of 4 percent to $15.58 billion from $15.05 billion in 2010. Earnings per share were $5.33 compared with $5.21 in 2010. Full-year adjusted net income was down 3 percent to $4.86 billion vs. $5.02 billion in 2010. Total product sales were up 4 percent, led by Xgeva (denosumab) at $351 million for the year. Prolia (denosumab) had $203 million in sales.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription